Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of bifeprunox in schizophrenia after studies 10206 or 10265
2005-000497-50Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bifeprunox in schizophrenia, sponsored by Lundbeck. Primary endpoints: Exploratory efficacy analyses and Long-term safety and tolerability of bifeprunox. Started Mar 2006; status: completed.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-000497-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000497-50.